Premium
Human umbilical cord blood cells directly suppress ischemic oligodendrocyte cell death
Author(s) -
Hall A.A.,
Guyer A.G.,
Leonardo C.C.,
Ajmo C.T.,
Collier L.A.,
Willing A.E.,
Pennypacker K.R.
Publication year - 2008
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.21857
Subject(s) - oligodendrocyte , neuroprotection , white matter , umbilical cord , pharmacology , ischemia , myelin basic protein , grey matter , medicine , anesthesia , myelin , immunology , central nervous system , endocrinology , magnetic resonance imaging , radiology
Previous reports have shown that human umbilical cord blood cells (HUCBCs) administered intravenously 48 hr following middle cerebral artery occlusion reduce infarct area and behavioral deficits of rodents. This cellular therapy is potently neuroprotective and antiinflammatory. This study investigates the effect of HUCBC treatment on white matter injury and oligodendrocyte survival in a rat model of ischemia. Intravenous infusion of 10 6 HUCBCs 48 hr poststroke reduced the amount of white matter damage in vivo as seen by quantification of myelin basic protein staining in tissue sections. To determine whether HUCBC treatment was protective via direct effects on oligodendrocytes, cultured oligodendrocytes were studied in an in vitro model of oxygen glucose deprivation. Active caspase 3 immunohistochemistry and the lactate dehydrogenase assay for cytotoxicity were used to determine that HUCBCs provide protection to oligodendrocytes in vitro. Based on these results, it is likely that HUCBC administration directly protects oligodendrocytes and white matter. This effect is likely to contribute to the increased behavioral recovery observed with HUCBC therapy. © 2008 Wiley‐Liss, Inc.